key: cord-0880679-9f0zysbv
authors: Khanmohammadi, Shaghayegh; Rezaei, Nima
title: Role of Toll‐like receptors in the pathogenesis of COVID‐19
date: 2021-02-09
journal: J Med Virol
DOI: 10.1002/jmv.26826
sha: 8128a9508bcb0afd6c29355d255ac469431e086e
doc_id: 880679
cord_uid: 9f0zysbv

Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has led to a pandemic since March 2020. The exact pathogenesis of SARS‐CoV‐2 and the role of each component of the innate and adaptive immune system is still unknown. However, available data from other coronavirus families, such as SARS‐CoV and the Middle East respiratory syndrome and also new findings could be useful for a better understanding of SARS‐CoV‐2. Toll‐like receptors (TLR) play an important role in recognition of viral particles and activation of the innate immune system. Activation of TLR pathways leads to secretion of pro‐inflammatory cytokines, such as interleukin‐1 (IL‐1), IL‐6, and tumor necrosis factor‐α, as well as type 1 interferon. Different TLRs, like TLR2, TLR3, TLR4, TLR6, TLR7, TLR8, and TLR9 are potentially important in COVID‐19 infection. It is also worth mentioning that we should bear in mind both the beneficial and harmful effects of TLR in confronting COVID‐19 infection. TLRs could be a potential target in controlling the infection in the early stages of disease and production of vaccine against SARS‐CoV‐2.

Toll-like receptors (TLRs) belong to the family of innate immune receptors, which play an important role in the activation of innate immunity, regulation of cytokine expression, indirect activation of the adaptive immune system, and the recognition of pathogenassociated molecular patterns (PAMPs). [1] [2] [3] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as novel coronavirus disease 2019 (COVID- 19) , has appeared in Wuhan, China, spread rapidly and led to a pandemic in 2020. 4 

TLRs have ten family members in humans. Some of the TLRs are located in the cell membrane, and the others are situated in endosomes, such as TLR3, TLR7, TLR8, and TLR9. 8 TLRs are expressed on different immune cells, such as dendritic cells (DCs), macrophages, natural killer cells, and cells of the adaptive immunity -T cells and B cells. 9 TLR3 recognizes double-strand RNA (ds RNA), TLR4 recognizes lipopolysaccharide (LPS), TLR7/8 recognizes single-strand RNA (ssRNA), and TLR9 recognizes unmethylated CpG DNA. 8 Myeloid differentiation primary response 88 (MyD88) and TIR-domain containing adaptor, inducing interferon-β (IFN-β) (TRIF, also known as TICAM1) are two main pathways for the transduction of TLR's signals. TRAF and IRAK proteins in signaling pathways cause activation of nuclear factor-kB (NF-kB) and Interferon regulatory factor (IRF), which in turn leads to the production of type 1 IFN and pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-6, tumor necrosis factor-α (TNF-α), and IL-12. Besides this, TLRs indirectly play role in the adaptive immune system by monitoring the expression of costimulatory molecules ( Figure 1 ).

Many viruses activate the innate immune system with TLRs, which contributes to the elimination of viruses, although it can also harm the host due to persistent inflammation and tissue destruction. For instance, severity of COVID-19 is associated with production of IL-6 in patients which could be produced by induction of TLR pathways. Activation of TLRs by SARS-CoV-2 leads to activation of inflammasome and production of IL-1β, which induces IL-6. Excessive activation of the inflammasome is associated with poor outcome in COVID-19 patients. 10 In addition, activation of Janus kinase transducers (JAK/STAT), which is induced by TLRs, could lead to macrophage activation syndrome.

Therefore, TLRs have a dual role in viral infections. 8, [11] [12] [13] [14] [15] Besides this, TLRs also contribute to the activation of the adaptive immune system via the upregulation of major histocompatibility complex on dendritic cells. 16 

Unfortunately, the exact pathway of the COVID-19 pathogenesis is still unknown. Therefore, most of the information regarding the COVID-19 pathogenesis arises from the available data about SARS-CoV and MERS-CoV. 9 Results of studies suggest that type 1 IFN plays an important role in SARS-CoV and MERS-CoV. They interfere with signaling pathways of the host cell and decrease the expression of IFN receptors, which in turn lead to a systemic inflammatory response. 9 As the production of type 1 IFN is mediated by TLRs, they could play a vital role in the pathogenesis of CoVs. Moreover, a cytokine storm exists in MERS-CoV, SARS-CoV, and SARS-CoV-2 that plays a crucial role in deterioration of these infections. 17 Several studies have shown that TLR3 via the TIRF pathway leads to a protective response in SARS-CoV and MERS-CoV infections. Although TLR3 in mouse models leads to activation of IRF3 and NF-kB pathways and production of type 1 IFN and pro-inflammatory cytokines, in knock-out mice for TLR3, no reduction in the secretion of these cytokines is seen in coronavirus infection.

Therefore, other pathways are also involved in the production of proinflammatory cytokines and type 1 IFN. 1 Induction of the TLR3 pathway, but not TLR2/4/7, in murine coronavirus infection in mouse models, stimulates the production of IFN-β in macrophages and hinders infection. 18 Besides this, MERS-CoV 4a protein can bind to dsRNA and suppress the production of type 1 IFN. 19 TLR4 also activates the same pathway. Although TLR4 plays a vital role in bacterial infections, it can be activated by oxidized phospholipids, which also appears in viral lung F I G U R E 1 Toll-like receptor signaling pathways. TLR2/6 and 4 localize in the cell membrane, and TLR3, TLR7/8, and 9 localize in the endosome surface. Activation of two major adaptive downstream proteins, MYS88 and TRIF, leads to production of pro-inflammatory cytokines and IFN I. Activation of TRIF induces activation of TRAF3, which activates IRF3 and leads to production of IFN I. MYD88 induces activation of TRAF6 in TLR2/6 as well as TLR4 pathway but leads to activation of IRAK4 and indirectly TRAF6 and TRAF3 in TLR7/9 and TLR9 pathway. Activation of NF-kB signaling through TRAF6 increases production of pro-inflammatory cytokines and activation of IRF7 leads to production of IFN I. dsRNA, double strand RNA; IFN I, interferon type 1; LPS, lipopolysaccharides; MYD88, myeloid differentiation primary response 88; NF-kB, nuclear factor k-light-chain-enhancer; ssRNA, single strand RNA; TRAF, tumor necrosis factor receptor-associated factor; TRIF, TIR-domain-containing adapter-inducing interferon-β infections. 1 In addition, neutrophil extracellular traps (NETs) are activated by the TLR4 signaling pathway. Studies have shown that NET formation in COVID-19 patients could lead to sustained inflammation which could deteriorate the condition of patients. Moreover, the higher production of TLR4 in men is due to a higher testosterone level; this fact can explain the higher level of pro-inflammatory cytokines in men compared to women. 20 Interestingly, neutrophil myeloperoxidase, which produces oxidized phospholipids, has a higher level in COVID-19 patients and also TLR4 pathway activation in the pulmonary phase of infection causes oxidative injury. Therefore, TLR4 could also be involved in the pathogenesis of COVID-19. 21, 22 An in silico study has also revealed a close relationship between bat SARS-CoV and SARS-CoV-2 (based on the spike protein and ACE2) and found that SARS-CoV-2 spike protein binds with TLR1, 4, and 6, with a higher affinity for TLR4.

TLR4 antagonist could be administered for treating COVID-19 patients. 23 According to another study, TLR8 is seen in the lung, and TLR7 and TLR8 could lead to a cytokine storm in SARS-CoV-1 and cause different side effects. 24 

SARS-CoV-2 has ssRNA + like other CoVs. Spike S glycoproteins on the SARS-CoV-2 envelope bind to angiotensin-converting enzyme 2 (ACE2) and the virus enters inside the cell by receptor-mediated endocytosis. 9 The results of several studies have shown that most of the patients suffer from lymphopenia and have elevated serum levels of pro-inflammatory cytokines, such as TNF-α, IL-6, and interleukin-2 receptor (IL-2R). It is also worth mentioning that higher serum levels CoV as it has more ssRNA motifs that could bind to TLR7. 32 Agonists of TLRs could lead to a strong immune response in COVID-19. 16 For instance, an innate immunity stimulator, Imiquimod, could be an option to control COVID-19. Imiquimod binds to TLR7/8 and induces the production of pro-inflammatory cytokines, such as TNF-α, IL-1, IL-2, IL-6, IL-8, IL-12, as well as IFN-α. However, it should be noticed that Imiquimod in the late stage of the infection could lead to cytokine storm and side effects of consistent inflammation. Therefore, Imiquimod is appropriate in the early stages of COVID-19 infection. 9 It should be mentioned that another candidate for triggering NET formation in COVID-19 patients is TLR7 and activation of TLR7/8 can induce a strong pro-inflammatory response in patients, leading to acute lung injury. Therefore, it may have a dual role in progression of the disease. 17, 33 Another clinical trial in China (ChiCTR2000029776) evaluates the therapeutic effects of the induction of TLR pathways in COVID-19 patients. Moreover, the TLR2/6/9 agonist is also ad- patients. For instance, CD24Fc conjugate is used to block TLR activation. 16 Also, using TLR4 antagonists such as glycyrrhetinic acid has anti-inflammatory effects in the lung of mice with acute respiratory distress syndrome, and protects the tissue from KHANMOHAMMADI AND REZAEI | 3 destruction due to inflammation. It may also stimulate an antiinflammatory activity downstream of the less active ACE2. Therefore, it could be a potential approach to control COVID-19. 34 Ramaiah suggested that mTOR inhibition and p53 activation could have therapeutic effects in COVID-19 patients. mTOR inhibitors play their role in the association of MyD88, IRF7, and the TLR9 pathways. 35 

COVID 19: a clue from innate immunity

Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes

Targeting of Toll-like receptors: a decade of progress in combating infectious diseases

Pathologic features of COVID-19: a concise review

COVID-19: developing from an outbreak to a pandemic

COVID-19: a chimera of two pandemics

Mesenchymal stem cells in COVID-19: a journey from bench to bedside

Toll-like receptors in antiviral innate immunity

Imiquimod-a toll like receptor 7 agonist-is an ideal option for management of COVID 19

The inflammasome in times of COVID-19

Recent insights into the role of Toll-like receptors in viral infection

Interleukin-6 and severe COVID-19: a systematic review and meta-analysis

SARS-CoV-2: A comprehensive review from pathogenicity of the virus to clinical consequences

Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective

Implications of Toll-like receptors in Ebola infection

Immune-mediated approaches against COVID-19

Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes

Protective role of Toll-like receptor 3-induced type I interferon in murine coronavirus infection of macrophages

Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control

Neutrophil extracellular traps (NETs) and damage-associated molecular patterns (DAMPs): two potential targets for COVID-19 treatment

Toll-like receptors and COVID-19: a two-faced story with an exciting ending

Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents

In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs

COVID-19 pandemic: is a gender-defined dosage effect responsible for the high mortality rate among males?

Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies

Targeting human TLRs to combat COVID-19: A solution?

Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection

COVID-19 patients upregulate Toll-like receptor 4-mediated inflammatory signaling that mimics bacterial sepsis

Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model

The immune system and COVID-19: Friend or foe?

Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection

Presence of genetic variants among young men with severe COVID-19

SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology

Symptomatic protective action of glycyrrhizin (Licorice) in COVID-19 infection?

mTOR inhibition and p53 activation, microRNAs: the possible therapy against pandemic COVID-19

The authors declare that there are no conflict of interests.

The peer review history for this article is available at https://publons. com/publon/10.1002/jmv.26826

https://orcid.org/0000-0002-3836-1827